Biophytis S.A.

Delisting Announcement • Feb 13, 2020

Biophytis shares trading is suspended pending a new press release

Paris (France), Cambridge (Massachusetts, U.S.), February 13, 2020, 08:00 CET - Biophytis SA (Euronext Growth Paris: ALBPS - FR0012816825) asked Euronext Paris to suspend the trading of its shares as from today the 13th of February 2020 before the opening of the stock exchange.

****

About Biophytis

Biophytis is a clinical-stage biotechnology company focused on developing therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, with a primary focus on neuromuscular diseases.

Biophytis' lead drug candidate, Sarconeos (BIO101) is an orally administered small molecule, which is currently in a Phase 2b clinical trial for sarcopenia (SARA-INT) in the U.S. and Europe. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne muscular dystrophy (DMD), for which the company was granted FDA IND approval in December 2019.

Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825).

For more information please visit www.biophytis.com

Biophytis Investor Relations Contact Evelyne Nguyen, CFO contact@biophytis.com

Europe Media Contact

Citigate Dewe Rogerson Sylvie Berrebi / David Dible / Nathaniel Dahan / Quentin Dussart biophytis@citigatedewerogerson.com Tel: +33 (0)1 55 30 70 91 / +44 (0)20 7638957

Source: Biophytis